OncoCyte Corp Cash Flow-to-Debt Ratio
OncoCyte Corp cash flow-to-debt ratio. OncoCyte Corp (OCX) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2025, meaning its operating cash flow of $-5.86 Million could theoretically repay 0% of its total liabilities ($50.14 Million) in one year. Check OncoCyte Corp cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of OncoCyte Corp (2013–2024)
Cash flow-to-debt ratio of OncoCyte Corp from 2013 to 2024. Historical debt coverage capacity for OncoCyte Corp across 12 annual periods. Check OncoCyte Corp (OCX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
OncoCyte Corp Cash Flow-to-Debt Ratio by Year (2013–2024)
OncoCyte Corp cash flow-to-debt ratio by year from 2013 to 2024. Year-by-year debt coverage analysis for OncoCyte Corp. For the full cash flow conversion analysis, see OncoCyte Corp cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.44x | $-20.71 Million | $47.35 Million | ▲ +7.6% |
| 2023 | -0.47x | $-23.32 Million | $49.30 Million | ▲ +31.7% |
| 2022 | -0.69x | $-45.57 Million | $65.80 Million | ▼ -81.8% |
| 2021 | -0.38x | $-35.94 Million | $94.35 Million | ▲ +67.8% |
| 2020 | -1.18x | $-25.98 Million | $21.94 Million | ▲ +45.8% |
| 2019 | -2.19x | $-19.71 Million | $9.02 Million | ▼ -14.3% |
| 2018 | -1.91x | $-11.65 Million | $6.09 Million | ▲ +17.0% |
| 2017 | -2.30x | $-13.38 Million | $5.81 Million | ▼ -40.4% |
| 2016 | -1.64x | $-7.52 Million | $4.58 Million | ▲ +10.2% |
| 2015 | -1.83x | $-4.23 Million | $2.31 Million | ▼ -1066.6% |
| 2014 | -0.16x | $-1.16 Million | $7.43 Million | ▼ -3.1% |
| 2013 | -0.15x | $-710.00K | $4.67 Million | — |